Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer.
The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.
Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F.
Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the District of Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 1, 23 | 0.00 Increased by +100.00% | -0.12 Increased by +100.00% |
| Aug 10, 23 | -0.11 Increased by +15.38% | -0.12 Increased by +8.33% |
| May 9, 23 | -0.12 Increased by +14.29% | -0.10 Decreased by -20.00% |
| Mar 28, 23 | -0.11 Increased by +15.38% | -0.03 Decreased by -266.67% |
| Nov 14, 22 | -0.12 Increased by 0.00% | -0.06 Decreased by -100.00% |
| Aug 9, 22 | -0.13 Increased by 0.00% | -0.15 Increased by +13.33% |
| May 3, 22 | -0.14 Increased by +6.67% | -0.13 Decreased by -7.69% |
| Mar 29, 22 | -0.13 Increased by +18.75% | -0.13 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 583.00 K Decreased by -15.01% | -9.96 M Increased by +16.71% | Decreased by -1.71 K% Increased by +2.00% |
| Mar 31, 23 | 731.00 K Increased by +12.12% | -10.63 M Increased by +14.54% | Decreased by -1.45 K% Increased by +23.77% |
| Dec 31, 22 | 543.00 K Increased by +20.40% | -8.77 M Increased by +24.72% | Decreased by -1.62 K% Increased by +37.47% |
| Sep 30, 22 | 712.00 K Increased by +66.36% | -10.55 M Increased by +1.49% | Decreased by -1.48 K% Increased by +40.79% |
| Jun 30, 22 | 686.00 K Increased by +33.98% | -11.95 M Decreased by -6.08% | Decreased by -1.74 K% Increased by +20.83% |
| Mar 31, 22 | 652.00 K Increased by +39.61% | -12.44 M Decreased by -6.94% | Decreased by -1.91 K% Increased by +23.40% |
| Dec 31, 21 | 451.00 K Increased by +3.44% | -11.65 M Decreased by -9.93% | Decreased by -2.58 K% Decreased by -6.27% |
| Sep 30, 21 | 428.00 K Decreased by -13.71% | -10.71 M Decreased by -12.37% | Decreased by -2.50 K% Decreased by -30.22% |